Ax­some's ap­proved de­pres­sion drug clears Alzheimer's ag­i­ta­tion tri­al months af­ter Lund­beck-Ot­su­ka duo

Af­ter an Au­gust ap­proval for treat­ing ma­jor de­pres­sive dis­or­der, Ax­some Ther­a­peu­tics’ tablet for­mu­la­tion of a cough sup­pres­sant and an­ti­de­pres­sant has now cleared a Phase III in an­oth­er in­di­ca­tion.

The drug, known in MDD as Au­veli­ty and un­der the in­ves­ti­ga­tion­al name AXS-05, was bet­ter than place­bo at de­lay­ing the time for ag­i­ta­tion re­lapse in pa­tients with Alzheimer’s, the New York biotech said Mon­day morn­ing. Topline da­ta from the Phase III showed AXS-05 was sta­tis­ti­cal­ly sig­nif­i­cant in de­lay­ing the time to re­lapse, with a p-val­ue of 0.014.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER